Navigation Links
Novel combination therapy shuts down escape route, killing glioblastoma tumor cells
Date:2/26/2013

February 26, 2013, New York, N.Y. and San Diego, Calif. Glioblastoma, the most common and lethal form of brain tumor in adults, is challenging to treat because the tumors rapidly become resistant to therapy. As cancer researchers are learning more about the causes of tumor cell growth and drug resistance, they are discovering molecular pathways that might lead to new targeted therapies to potentially treat this deadly cancer.

Scientists at the Ludwig Institute for Cancer Research in San Diego worked collaboratively across the laboratories of Drs. Paul Mischel, Web Cavenee and Frank Furnari to investigate one such molecular pathway called the mammalian target of rapamycin or mTOR. This signaling pathway is hyperactivated in close to 90 percent of glioblastomas and plays a critical role in regulating tumor growth and survival. Therapies that inhibit mTOR signaling are under investigation as drug development targets, but results to date have been disappointing: mTOR inhibitors halt the growth but fail to kill the tumor cells.

A study published this week in the Proceedings of the National Academy of Sciences uncovers an unexpected but important molecular mechanism of mTOR inhibitor resistance and identifies a novel drug combination that reverses this resistance.

The story begins with a closer look at a gene-encoded protein called promyleocytic leukemia gene or PML. The study investigators explored the role of PML in causing resistance to mTOR inhibitor treatment. They found that when glioblastoma patients are treated with drugs that target the mTOR pathway, the levels of PML rise dramatically. Further, they showed that PML upregulation made the tumor cells resistant to mTOR inhibitors, and that if they suppressed the ability of the tumor cells to upregulate the PML protein, the tumor cells died in response to the mTOR inhibitor therapy.

"When we looked at cells in in vivo models and patients treated in the clinic, i
'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers discover novel therapy for Crohns disease
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Notre Dame researchers using novel method to combat malaria drug resistance
4. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
5. Key proteins newly discovered form and function may provide novel cancer treatment target
6. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
7. London researchers discover novel mechanism involved in key immune response
8. Mexican rock heroes trial novel green trading system
9. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
10. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
11. Novel nano-structures to realize hydrogens energy potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that four of its fingerprint ID products, ... been named FIDO Certified™ by the Fast IDentity ... Synaptics, Natural ID™ fingerprint solutions are fully compliant ... standard and are interoperable among other products and ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... Sacred Seeds, an international non-profit that supports plant ... and cultural knowledge, has extended its reach to ... are in Saint-Ay, France. Sacred Seeds is ... plants of medicinal and cultural significance. The program ...
... of lung edema, or fluid in the lungs, not only do ... they are also allowing water to pump in. "Usually, our ... previously believed that this pump mechanism just stopped when people had ... Hospital. "But we,ve found not only do they stop pumping fluid ...
... MD FASEB MARC (Maximizing Access to Research Careers) ... 2013 American College of Sports Medicine (ACSM) 60th Annual ... in Indianapolis, IN from May 28 June 1, ... of students, postdoctorates and scientists from underrepresented groups into ...
Cached Biology News:Missouri Botanical Garden program annouces collaboration with L'Herboretum 2MARC travel awards announced for the 2013 60th Annual ACSM Meeting & 4th World Congress 2
(Date:9/2/2015)... September 2, 2015 BiondVax Pharmaceuticals Ltd. ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... of Health and Human Services (HHS), to launch a new ... United States in the 2015-16 timeframe. The trial ... Multimeric-001 (M-001), as a primer vaccine, which would be administered ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical ... From vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ... real-time clinical decisions with simultaneous access to high precision medical images and electronic ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficiency of their entire waste to energy process and continue to contribute to ... Major Upgrade , Temarry’s Waste to Energy process has been operating at their ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, a ... today unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery 2015. ... market a rich set of new capabilities. Screener now supports High Throughput Flow ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... TRIANGLE PARK, N.C., Jan. 14, 2011 Talecris Biotherapeutics Holdings ... has established a new record date and meeting date for ... announced merger agreement under which Grifols (GRF.MC) will acquire TLCR. ... business on January 11, 2011 will be entitled to vote ...
... 14, 2011 Accuray Incorporated (Nasdaq: ARAY ), ... that it will report results for its second quarter of ... 2011 after the market closes. A conference call ... p.m. ET and will be hosted by Euan S. Thomson, ...
... Fla., Jan. 13, 2011 GeneLink, Inc. ... consumer genomics biotech company, has announced that Robert B. ... recently formed a company to distribute genetically customized products ... intends to market the product line utilizing techniques similar ...
Cached Biology Technology:Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011 2GeneLink Announces New Licensing Partner 2GeneLink Announces New Licensing Partner 3
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
McCoy's 5A Medium. Without Tryptose or Phosphate Broth. Contains Sodium Bicarbonate....
... fast and specific detection of chromosomal sequences ... hybridisation time ( Works ... Multiplex capability Available with different tags ... available with different labels. Related Content: ...
... a K-12 strain ideally suited as an ... transformation efficiency, blue/white screening capability (with appropriate ... in high yields of excellent quality plasmid ... potentially useful as a stringent host due ...
Biology Products: